Back to the main directory
EarningsReview / Equity
- Omicron headwind but 20% growth expected for FY22 by BNP Paribas Exane
- Divisions weak but dividends strong by BNP Paribas Exane
- FY21 results and 15 questions for management by BNP Paribas Exane
- Q421 results and 15 questions for management by BNP Paribas Exane
- AFRY - Growing in numbers by Danske Bank Equity Research
- AddLife - Forming a European one-stop-shop for life sciences by Danske Bank Equity Research
- Epiroc - Aftermarket growth supportive for profitability by Danske Bank Equity Research
- Atlas Copco - Buy/SEK 640: Still on track by Nordea
- Essity - Buy/SEK 320: Margins to start recovering in Q2 by Nordea
- Topdanmark - Buy/DKK 450: 20% margin improvement from 2021E to 2025E by Nordea
- Embracer Group (Buy, TP: SEK155.00) - Gathering IP across the board by DnB Markets
- Oncopeptides (Buy, TP: SEK15.00) - Almost back to status quo by DnB Markets
- Genmab (Buy, TP: DKK2950.00) - BUY the uncertainty by DnB Markets
- Essity (Buy, TP: SEK320.00) - Set for solid Q4 results by DnB Markets
- Tryg (Buy, TP: DKK182.00) - Delivering according to plan by DnB Markets
- Tryg (Buy, TP: DKK182.00) - Delivering according to plan by DnB Markets
- Coloplast (Hold, TP: DKK1000.00) - A good start to the year by DnB Markets
- Carasent (Buy, TP: NOK50.00) - Still solid prospects despite hurdles by DnB Markets
- Ambu (Buy, TP: DKK250.00) - Weak Q1 and Omicron uncertainty by DnB Markets
- Novo Nordisk (Buy, TP: DKK740.00) - Headwinds well reflected by DnB Markets
- Euronav (Hold, TP: USD9.40) - Oversupply headache by DnB Markets
- Neles (Hold, TP: EUR12.50) - No drama by DnB Markets
- Seafood - Fat Trout Weekly by DnB Markets
- AAC Clyde Space - Preparing to AACcelerate growth by Edison Investment Research
- Atlantis Japan Growth Fund - Outperformance and a high income, at a discount by Edison Investment Research
- Encouraging messaging on cash returns by BNP Paribas Exane
- A safe haven amidst the inflation storm by BNP Paribas Exane
- FY21 - Small beat on one-offs by BNP Paribas Exane
- Itaú BBA on Banco de Chile: Getting the Ring! by Itau
- Target Healthcare REIT - Capital deployment and positive returns by Edison Investment Research
- Tele2 - A potential pile of cash by Danske Bank Equity Research
- 2020 Bulkers Ltd - Dividend booster by Danske Bank Equity Research
- Ericsson - Buy/SEK 132 (128): R&D paying off by Nordea
- HMS Networks - Hold: Hats off to the supply chain team by Nordea
- TF Bank - Buy/SEK 242: Cautious DPS but EPS story remains intact by Nordea
- Atea (Buy, TP: NOK195.00) - Continues to look attractive by DnB Markets
- Pandox (Buy, TP: SEK175.00) - Omicron hits near-term forecasts by DnB Markets
- Ossur (Buy, TP: DKK51.00) - Set for conservative guidance by DnB Markets
- Tele2 (Buy, TP: SEK145.00) - Dividend and outlook in focus by DnB Markets
- Atlas Copco (Hold, TP: SEK570.00) - Demand solid but margins lagging by DnB Markets
- Carlsberg (Hold, TP: DKK1175.00) - Eyes on 2022 guidance by DnB Markets
- TietoEVRY (Buy, TP: EUR38.00) - Continued gradual improvement by DnB Markets
- HMS Networks (Hold, TP: SEK485.00) - Riding the automation wave by DnB Markets
- Norsk Hydro (Hold, TP: NOK70.00) - Supported by high energy prices by DnB Markets
- SKF (Hold, TP: SEK205.00) - Unable to convince the market by DnB Markets
- Trelleborg (Buy, TP: SEK285.00) - Record-strong backlog by DnB Markets
- Dorian LPG Minor model adjustments by DnB Markets
- Valid interest rate concerns by DnB Markets
- IQE - New CEO – new engagement with markets by Edison Investment Research
- Hostmore - Ready to party by Edison Investment Research